The economics of reproducibility in preclinical research
Files
Published version
Date
2015-06-01
Authors
Freedman, Leonard P.
Cockburn, Iain M.
Simcoe, Timothy S.
Version
Published version
OA Version
Citation
Leonard P Freedman, Iain M Cockburn, Timothy S Simcoe. 2015. "The Economics of Reproducibility in Preclinical Research." PLoS Biology, Volume 13, Issue 6, 9 pp. https://doi.org/10.1371/journal.pbio.1002165
Abstract
Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development. An analysis of past studies indicates that the cumulative (total) prevalence of irreproducible preclinical research exceeds 50%, resulting in approximately US$28,000,000,000 (US$28B)/year spent on preclinical research that is not reproducible—in the United States alone. We outline a framework for solutions and a plan for long-term improvements in reproducibility rates that will help to accelerate the discovery of life-saving therapies and cures.
Description
License
Copyright: © 2015 Freedman et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited